Targeted Drug Delivery (TDD) for Treatment in Patients Suffering with Cancer-Related Pain.

1. Participants will be able to demonstrate the effectiveness of Targeted Drug Delivery on pain scores and quality of life for patients with cancer related pain. 2. Participants will be able to demonstrate the impact of Targeted Drug Delivery on decreasing both ER and hospital visits for cancer related pain. Addressing and treating pain in cancer is a vital component of Palliative Care. Targeted Drug Delivery (TDD) is an underutilized tool for managing cancer pain yet can improve quality of life and decrease costs. We present data that TDD demonstrates decreased pain scores, improved quality of life and decreased patient utilization of both ED and hospital. A 2017 systematic review and meta-analysis reports cancer pain as prevalent in over 50% of patients undergoing cancer treatment, and in about 66% of patients with later stages of the disease¹. Pain is associated with decreased quality of life and distress in cancer patients, with associated symptoms of fatigue, insomnia, and loss of appetite². Targeted drug delivery (TDD) is approved for the treatment of chronic malignant and nonmalignant pain since 1991. A recent systematic review across 29 clinical studies demonstrated that TDD effectively reduced pain and opioid use at follow-up compared with baseline³. Additionally, cost-effectiveness has been demonstrated4. An analysis of TDD on the Quality of Life (QoL) in cancer patients is needed to better understand the therapy approach as a treatment option. Information is summarized from current literature and an ongoing TDD registry called the Product Surveillance Registry (PSR), a prospective, long-term, multi-center registry. After providing informed consent, patients are followed through end-of-life with data collected on QoL, pain scores, safety, and device performance. An ad hoc analysis of registry data summarizing adverse events, pain scores, and QoL changes will be completed on enrolled patients with baseline QoL scores. Additional assessment of Oncologic outcomes pending. Since 2003, 9896 patients were enrolled in the PSR across 76 sites. Data on QoL, pain scores, and adverse events will be summarized at baseline, 1-3, 6-12, and 24 months. Both mean pain scores and mean EQ-5D scores showed statistically significant improvement from baseline to 6- and 12-month follow-ups. A previously published study found mean health care utilization and commercial payer costs were significantly lower with TDD compared to conventional medical management with a decrease at 2 months of $15,152 and $63,498 at 1 year4. TDD is a safe and cost-effective therapeutic option for the treatment of cancer pain. Management of Medical Interventions / Innovative Technologies [ABSTRACT FROM AUTHOR]

Copyright of Journal of Pain & Symptom Management is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)